Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

Gilead / GS-US-595-6184

Trial Overview

Official Title

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05 / OptimICE-RD)

Diagnosis

Triple negative breast cancer which is defined as hormone receptor negative and HER2 receptor negative

Eligibility

Must have completed treatment prior to surgery, and at time of surgery, pathology shows that some breast cancer is still active after therapy 

 

Intervention

Treatment after surgery:  Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice

 

 

For more information, click the link below:

 

https://clinicaltrials.gov/study/NCT05633654?term=GS-US-595-6184&rank=1

 

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Male or Female
Age
19 years and over
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
GS-US-595-6184